[1,3] dioxolo [4,5-g] [1,2,4] triazolo [1,5-a] quinoline derivatives as inhibitors of the late SV40 factor (LSF) for use in treating cancer

1. A compound of structural formula XIV, XV or XVI;

or a pharmaceutically acceptable salt thereof wherein,

each X is independently O or S;

R 1 is hydrogen or an alkyl, alkenyl, alkynyl, aryl, heteroaryl or arylalkyl group;

R 2 is hydrogen or a hydroxyl, alkoxy, phenoxy, alkyl, alkenyl, alkynyl, aryl, heteroaryl or arylalkyl group;

each R 3 and each R 6 is: (i) independently hydrogen, fluorine, chlorine, bromine, iodine or a hydroxyl, alkoxy, phenoxy, alkyl, alkenyl, alkynyl, aryl, heteroaryl or arylalkyl group; or (ii) the two R 6 moieties and/or the two R 3 moieties taken together with an alkylene, alkenylene or alkynylene group form a substituted or unsubstituted C3 to C6 ring; and

R 4 , R 5 , R 7 , R 8 , R 9 , R 10 R 11 and R 12 are each independently hydrogen, fluorine, chlorine, bromine, iodine or a hydroxyl, alkoxy, phenoxy, alkyl, alkenyl, alkynyl, aryl, heteroaryl or arylalkyl group.

2. The compound of claim 1 , wherein for structural formulas XIV, XV or XVI:

each X is O or S;

R 1 is hydrogen or a methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, sec-butyl, substituted or unsubstituted phenyl or substituted or unsubstituted benzyl group;

R 2 is hydrogen or a hydroxyl, methoxy, ethoxy, methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, sec-butyl, phenyl or benzyl group;

each R 3 and each R 6 is independently hydrogen, fluorine, chlorine, bromine, iodine or a hydroxyl, methoxy, ethoxy, methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, sec-butyl, phenyl or benzyl group; and

R 4 , R 5 , R 7 , R 8 , R 9 , R 10 R 11 and R 12 are each independently hydrogen, fluorine, chlorine, bromine, iodine or a hydroxyl, methoxy, ethoxy, methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, sec-butyl, phenyl or benzyl group.

3. The compound of claim 2 , wherein the compound of structural formula XIV, XV or XVI is a compound having the structural formula IV, V or VI;

or a pharmaceutically acceptable salt thereof.

4. A composition comprising a compound of formula XIV, XV or XVI;

or a pharmaceutically acceptable salt thereof wherein,

each X is independently O or S;

R 1 is hydrogen or an alkyl, alkenyl, alkynyl, aryl, heteroaryl or arylalkyl group;

R 2 is hydrogen or a hydroxyl, alkoxy, phenoxy, alkyl, alkenyl, alkynyl, aryl, heteroaryl or arylalkyl group;

each R 3 and each R 6 is: (i) independently hydrogen, fluorine, chlorine, bromine, iodine or a hydroxyl, alkoxy, phenoxy, alkyl, alkenyl, alkynyl, aryl, heteroaryl or arylalkyl group; or (ii) the two R 6 moieties and/or the two R 3 moieties taken together with an alkylene, alkenylene or alkynylene group form a substituted or unsubstituted C3 to C6 ring; and

R 4 , R 5 , R 7 , R 8 , R 9 , R 10 R 11 and R 12 are each independently hydrogen, fluorine, chlorine, bromine, iodine or a hydroxyl, alkoxy, phenoxy, alkyl, alkenyl, alkynyl, aryl, heteroaryl or arylalkyl group.

5. The composition of claim 4 , wherein for the compound of formula XIV, XV or XVI:

each X is O or S;

R 1 is hydrogen or a methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, sec-butyl, substituted or unsubstituted phenyl or substituted or unsubstituted benzyl group;

R 2 is hydrogen or a hydroxyl, methoxy, ethoxy, methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, sec-butyl, phenyl or benzyl group;

each R 3 and each R 6 is independently hydrogen, fluorine, chlorine, bromine, iodine or a hydroxyl, methoxy, ethoxy, methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, sec-butyl, phenyl or benzyl group; and

R 4 , R 5 , R 7 , R 8 , R 9 , R 10 R 11 and R 12 are each independently hydrogen, fluorine, chlorine, bromine, iodine or a hydroxyl, methoxy, ethoxy, methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, sec-butyl, phenyl or benzyl group.

6. The composition of claim 5 , wherein the compound of structural formula XIV, XV or XVI is a compound having the structural formula IV, V or VI:

or a pharmaceutically acceptable salt thereof.

7. The composition of claim 4 , wherein said composition further comprises a pharmaceutically acceptable carrier.

8. A method comprising administering to a subject, to inhibit or treat LSF in said subject, an effective amount of a compound of structural formula XIV, XV or XVI;

or a pharmaceutically acceptable salt thereof, wherein,

each X is independently O or S;

R 1 is hydrogen or an alkyl, alkenyl, alkynyl, aryl, heteroaryl or arylalkyl group;

R 2 is hydrogen or a hydroxyl, alkoxy, phenoxy, alkyl, alkenyl, alkynyl, aryl, heteroaryl or arylalkyl group;

each R 3 and each R 6 is: (i) independently hydrogen, fluorine, chlorine, bromine, iodine or a hydroxyl, alkoxy, phenoxy, alkyl, alkenyl, alkynyl, aryl, heteroaryl or arylalkyl group; or (ii) the two R 6 moieties and/or the two R 3 moieties taken together with an alkylene, alkenylene or alkynylene group form a substituted or unsubstituted C3 to C6 ring; and

R 4 , R 5 , R 7 , R 8 , R 9 , R 10 R 11 and R 12 are each independently hydrogen, fluorine, chlorine, bromine, iodine or a hydroxyl, alkoxy, phenoxy, alkyl, alkenyl, alkynyl, aryl, heteroaryl or arylalkyl group.

9. A method of determining the expression or activity of LSF comprising:

a) contacting a cancerous cell or cancerous tissue with a compound of claim 1 ; and

b) monitoring, directly or indirectly, the expression or activity of LSF associated with said cancerous cell or cancerous tissue.

10. A method of determining the expression or activity of LSF comprising:

a) contacting a cancerous cell or cancerous tissue with a composition of claim 4 ; and

b) monitoring, directly or indirectly, the expression or activity of LSF associated with said cancerous cell or cancerous tissue.